Opioid maker Grünenthal readies high yield debut months after freeze-out
Grünenthal, the German pharmaceutical firm which specialises in painkillers, is looking to refinance its debt with an inaugural high yield bond, just two months after buyers reportedly shunned the company over ESG concerns around opioid manufacturing.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: